Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 13/20 | 0.59 |
| ▸ | ACACA | Q13085 | 13/20 | 0.59 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | OTUD7B | Q6GQQ9 | 2/20 | 0.32 |
| ▸ | STK10 | O94804 | 1/20 | 0.32 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.32 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2362487 | 0.91 | ACACB (0.64) | ACACBACACA | |
| SCHEMBL11888077 | 0.90 | ACACB (0.73) | ACACBACACA | |
| SCHEMBL2361925 | 0.89 | ACACB (0.56) | ACACBACACAOTUD7BSTK10SLK | |
| SCHEMBL29735375 | 0.86 | ACACB (0.53) | ACACBACACA | |
| SCHEMBL249181 | 0.86 | ACACB (0.53) | ACACBACACA | |
| SCHEMBL12540243 | 0.86 | ACACB (0.79) | ACACBACACACNR1CNR2TNKS2 | |
| SCHEMBL12256245 | 0.85 | ACACB (0.45) | ACACBACACACNR1CNR2 | |
| SCHEMBL12029732 | 0.85 | ACACB (0.60) | ACACBACACATNKS2 | |
| SCHEMBL12456400 | 0.85 | ACACB (0.54) | ACACBACACAKCNH2TNKS2 | |
| SCHEMBL2362922 | 0.84 | ACACB (0.44) | ACACBACACASSTR5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9809542-B2 | Spiroheterocyclically substituted tetramic acid derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-11-07 | — | — | US | disclosed |
| US-9809542-B2 | Spiroheterocyclically substituted tetramic acid derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-11-07 | — | — | US | disclosed |
| US-9809542-B2 | Spiroheterocyclically substituted tetramic acid derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-11-07 | — | — | US | disclosed |
| EP-2534147-B1 | SPIROHETEROCYCLIC-SUBSTITUTED TETRAMIC ACID DERIVATIVES | BAYER IP GMBH (DE) | 2015-06-17 | — | — | EP | disclosed |
| EP-2534147-A1 | SPIROHETEROCYCLICAL SUBSTITUTED TETRAMIC ACID DERIVATIVES | Bayer Intellectual Property GmbH (DE) | 2012-12-19 | — | — | EP | disclosed |
| US-20110230351-A1 | Spiroheterocyclically Substituted Tetramic Acid Derivatives | BAYER CROPSCIENCE AG (DE) | 2011-09-22 | — | — | US | disclosed |
| US-20110230351-A1 | Spiroheterocyclically Substituted Tetramic Acid Derivatives | BAYER CROPSCIENCE AG (DE) | 2011-09-22 | — | — | US | disclosed |
| US-20110230351-A1 | Spiroheterocyclically Substituted Tetramic Acid Derivatives | BAYER CROPSCIENCE AG (DE) | 2011-09-22 | — | — | US | disclosed |
| WO-2011098443-A1 | SPIROHETEROCYCLICAL SUBSTITUTED TETRAMIC ACID DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011098443-A1 | SPIROHETEROCYCLICAL SUBSTITUTED TETRAMIC ACID DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230351-A1 | Spiroheterocyclically Substituted Tetramic Acid Derivatives | AGXT, PTPRG, WIZ | ACACB 904/4885ACACA 192/4885CNR1 3516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.